Hands-on Tablet Development, including Pre-formulation, Formulation and Process Development 25 May 2016 08:30 - 27 May 2016 17:00, Croydon, Greater London, United ... Project team members needing a ...

Viking previously reported positive results from a 28-day Phase 1 multiple ascending dose (MAD) clinical trial of the tablet formulation of VK2735 in healthy volunteers with a BMI ≥30.

The Food and Drug Administration (FDA) has approved a tablet formulation of Evrysdi ® (risdiplam) for the treatment of spinal muscular atrophy (SMA). Previously, the treatment had only been ...

The acquisition of Avivia aligns with Ofichem’s broader merger and acquisition agenda and ongoing investment strategy.

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA ... The global BRUKINSA clinical development program includes about 7,100 patients enrolled in 30 countries and regions across more than ...

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA ®. BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that ...